This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Gilead Sciences, Inc.

Drug Names(s): Racivir

Description: Racivir is cytosine analog and is a nucleoside analogue reverse transcriptase inhibitor (NRTI) closely related in structure to Emtriva.

Deal Structure: In 1998, Pharmasset licensed Racivir from Emory University pursuant to an exclusive, worldwide license agreement to make, have made, use, import, offer for sale and sell Racivir.

In November 2011, Gilead and Pharmasset announced that the companies have signed a definitive agreement under which Gilead will acquire Pharmasset for $137 per share in cash. The transaction values Pharmasset at approximately $11 billion. In January 2012, Gilead announced the successful completion of the tender offer for all of the outstanding shares of common stock of Pharmasset.

Racivir News

Pink Sheet Trademark Review

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug